Cases & Deals

  • Home
  • Practices
  • BioMarin acquires Amicus Therapeutics for $4.8 billion

Share

BioMarin acquires Amicus Therapeutics for $4.8 billion

December 2025

Client(s) BioMarin Pharmaceutical Inc.

Jones Day is advising BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) in its $4.8 billion acquisition of Amicus Therapeutics (Nasdaq: FOLD).

The acquisition will strengthen BioMarin’s commercial portfolio, adding two new treatments to the company’s existing portfolio of medicines that target lysosomal storage disorders: Galafold® (migalastat), the first oral treatment for Fabry disease and Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat), a two-component therapy for Pompe disease.

The transaction is expected to close in the second quarter of 2026, subject to regulatory clearances, approval by the stockholders of Amicus and other customary closing conditions.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.